Results 151 to 160 of about 50,656 (201)
Some of the next articles are maybe not open access.
Glucagon-like Peptide-1 Receptor Agonists
2021Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire +1 more source
Overview of Glucagon-like Peptide-1 Receptor Agonists
Home Healthcare Now, 2015Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists
Incretin hormones are glucoregulatory neurohormones, and GLP-1 and GIP account for about 90% of the incretin effect.1 GLP-1 and GIP are secreted in response to food ingestion and act on the pancreas to stimulate glucose-dependent insulin secretion and blunt inappropriate glucagon secretion ...Heather P. Whitley, Jennifer M. Trujillo
+4 more sources
Renal protection with glucagon-like peptide-1 receptor agonists
Current Opinion in Pharmacology, 2020There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M. +3 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Advances in Chronic Kidney Disease, 2021In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at fasting and in the postprandial phase without an increased ...
Tricò, Domenico, Solini, Anna
openaire +3 more sources
Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Kardiologiia, 2014In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov +2 more
openaire +2 more sources
Obesity and Glucagon-Like Peptide-1 Receptor Agonists
JAMAThis Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
Trends in Endocrinology & Metabolism, 2016Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire +4 more sources
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source